In high-risk patients with cancer, thromboprophylaxis with rivaroxaban did not reduce VTE events at 180 days
- PMID: 31207620
- DOI: 10.7326/ACPJ201906180-067
In high-risk patients with cancer, thromboprophylaxis with rivaroxaban did not reduce VTE events at 180 days
Comment on
-
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630. N Engl J Med. 2019. PMID: 30786186 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources